I'ROM GROUP

  • Message
  • Company Profile
  • Business Partnership
  • News
  • Press Release
  • Contact Us
  • Links

Press Release

Reference: Director/Administration Manager: Isamu Hara

Date Medium Content
2015/4/1 - DNAVEC Corporation Changes Company Name to ID Pharma Co., Ltd.
2012/11/13 - Notice on the conclusion of Strategic Partnership Agreement with I'ROM Holdings Co. Ltd.
2011/10/31 - On the completion of a PreIND meeting between the International AIDS Vaccine Initiative (IAVI) and the USFDA regarding the prophylactic AIDS vaccine
2011/10/13 - DNAVEC Corporation announces the publication of a research paper in the journal Nature reporting a gene repair therapy using iPS cells from patients with severe monogeneic disease
2011/9/26 - On the out-licensing of a prophylactic AIDS vaccine technology and the initiation of a clinical trial
2011/8/02 - Development of a controled gene expression period-type vector that leaves no foot-print in the cells and its use in the generation of iPS cells from umbilical cord blood
2011/6/22 - Notice on the out-licensing of a tumor therapeutic to a Chinese company
2011/5/20 - Publication of the completion report of the clinical research by Kyushu University on the angiogenic gene therapeutic for limb ischemia
2011/4/27 NIHON KEIZAI SHINBUN Launching a Kit for iPS cell Generation to the Market Outside of Japan
2010/11/10 NIHON KEIZAI SHINBUN DNAVEC concludes a licensing agreement with a Biotech Company of China on retinitis pigmentosa therapeutics.
2010/06/15 - On the launch of the iPS cell preparation kit
2009/10/08 - Notice on the offer of chromosomal damage-free iPS cell preparation kit
2009/10/02 - Notice on the academic publication regarding the method for the preparation of chromosomal damage-free iPS cells.
2009/04/29 - On the technological partnership with Daiichi Sankyo Co., Ltd. regarding antibody therapeutics
2009/04/09 - On the conclusion of a collaborative research agreement with Sichuan University of China regarding gene therapeutics for glaucoma
2008/04/01 - DNAVEC concludes a collaborative development agreement with Chinese Academy of Sciences on the development of Avian Influenza vaccine.
2007/05/25 - DNAVEC concludes a licensing agreement with SiBiono of China on AIDS vaccine.
2006/07/04 - A new concept of gene therapy enters a clinical study: the Japan-made gene therapy vector, Sendai virus vector, was administered to a patient for the first time at the Kyushu University Hospital.
2006/03/31 - DNAVEC and Eisai sign an agreement on drug discovery research for the development of gene vaccine for Alzheimer’s disease.
2006/01/16 - DNAVEC was granted the patent "AIDS virus vaccines using Sendai virus vector" in China.
2005/11/15 NIHON KEIZAI SHIMBUN
(morning edition p12)
HIV Vaccine development in China: clinical trial to start in 2006.
2005/10/12 - MHLW approves the Kyushu University Hospital's plan for a clinical study of gene therapy: the start of a new concept of gene therapy.
2005/08/24 NIKKEI SANGYO SHIMBUN
(morning edition p1)
Vaccines change the world of medicine: Competition for the drugs for Alzheimer’s disease heats up.
2005/06/29 - DNAVEC was granted the master patent of Sendai virus vectors in major countries.
2005/06/17 - DNAVEC and Medical & Biological Laboratories Co., Ltd (MBL) found a joint venture in Beijing, China.
2005/06/09 - DNAVEC and National Institute for Longevity Sciences announce a joint development of intranasal vaccines for the treatment of Alzheimer’s disease.
2005/04/13 - DNAVEC announces the launching of the "CKD New Generation Cancer Gene Therapy Research Consortium" involving Chiba University, Kyusyu University and DNAVEC, and the opening of a core research chair for the program sponsored by DNAVEC.
2005/04/11 NIKKEI SANGYO SHIMBUN
(morning edition p12)
“Social Lounge: Surviving by multinational expansion,” an interview with Dr. Mamoru Hasegawa, President and CEO of DNAVEC.
2005/02/17 - DNAVEC concludes a joint research agreement with Kringle Pharma, Inc. on the development of gene medicine.
2004/12/07 - DNAVEC announces business alliance with Medical & Biological Laboratories Co., Ltd. (MBL) on the use of Sendai virus vector.
2004/12/01 - DNAVEC concludes an licensing agreement on a gene therapeutic medicine to Beijing Pharmaceutical Group Co., Ltd.
2004/10/07 NIHON KEIZAI SHIMBUN
(morning edition p16)
DNAVEC announces a capital increase of ¥1,900 Million funded by Dream Incubator Inc.
2004/05/01 WEEKLY TOYOKEIZAI
2004.5.1-8
Hideaki Sena’s monthly interview series, "Invitation to Science Part 2" with Dr. Mamoru Hasegawa, President and CEO of DNAVEC, "Gene therapy will become something like drugs for common cold."
2003/11/07 NIHON KEIZAI SHIMBUN
(morning edition p17)
An AIDS vaccine will be developed by Japan-China collaboration; DNAVEC Res. Inc. receives a promising gene.
2003/07/07 NIKKEI SANGYO SHIMBUN
(morning edition p9)
RNA opens a new avenue to bio-business part1: Safer gene therapy using Sendai virus vectors; clinical trials planned at universities in Japan and overseas.
2003/06/26 NIHON KEIZAI SHIMBUN,
Ibaraki Section
(morning edition p41)
DNAVEC Research Inc. develops a "carrier" of genes (North Kanto VB file).
2003/06/13 NIKKEI SANGYO SHIMBUN
(morning edition p10)
DNAVEC Research Inc. test-produces SARS vaccine by August in collaboration with Beijing University of Technology; animal experiments are planned in China.
2002/08/26 NIKKEI BIOTECH DNAVEC Research Inc. receives a grant for CF gene therapy using Sendai virus vectors.
2001/09/03 YAKUJI NIPPO DNAVEC Research Inc. develops a new viral vector for the gene therapy for Critical Limb Ischemia.
2001/08/02 NIKKEI SANGYO SHIMBUN
(morning edition p11)
DNAVEC Research Inc. transfers genes into monkey ES cells with an efficiency of 90%.
2001/07/20 NIHON KEIZAI SHIMBUN
(morning edition p17)
DNAVEC Research Inc. develops an effective “carrier” for gene therapy; clinical trial planned in UK.
2001/07/02 NIKKEI BIOTECH DNAVEC and Kyushu University forms a research consortium aiming at utilization of DNAVEC’s Sendai virus vectors.
2001/02/05 NIKKEI SANGYO SHIMBUN
(morning edition p11)
DNAVEC Research Inc. develops a Japan-made vector for gene therapy.
2000/11/18 NIHON KEIZAI SHIMBUN
(morning edition p13)
Gene therapy; accelerated commercialization targeting lifestyle-related diseases.
2000/09/25 NIHON KEIZAI SHIMBUN
(morning edition p17)
DNAVEC Research Inc. develops a high performance gene carrier, a Japanese original.